Crispr Therapeutics AG (NASDAQ:CRSP) has received a consensus rating of "Buy" from the eighteen analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and twelve have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $95.54.
CRSP has been the subject of a number of research analyst reports. SunTrust Banks initiated coverage on Crispr Therapeutics in a research report on Tuesday, July 14th. They issued a "buy" rating and a $140.00 target price for the company. Roth Capital boosted their target price on Crispr Therapeutics from $100.00 to $105.00 and gave the company a "buy" rating in a research report on Friday, June 19th. Citigroup reaffirmed a "sell" rating on shares of Crispr Therapeutics in a research report on Wednesday, August 5th. Barclays boosted their target price on Crispr Therapeutics from $65.00 to $102.00 and gave the company an "overweight" rating in a research report on Tuesday, July 28th. Finally, BidaskClub upgraded Crispr Therapeutics from a "hold" rating to a "buy" rating in a research note on Wednesday, September 2nd.
In other news, Director Bradley J. Phd Bolzon sold 20,000 shares of the business's stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $82.39, for a total value of $1,647,800.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Bradley J. Phd Bolzon sold 60,000 shares of the company's stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $92.51, for a total value of $5,550,600.00. The disclosure for this sale can be found here. Insiders sold a total of 178,000 shares of company stock worth $15,962,543 in the last 90 days. Company insiders own 17.10% of the company's stock.
A number of institutional investors have recently bought and sold shares of the stock. Sandy Spring Bank lifted its stake in Crispr Therapeutics by 13.0% in the second quarter. Sandy Spring Bank now owns 1,053 shares of the company's stock valued at $77,000 after purchasing an additional 121 shares during the last quarter. Slow Capital Inc. lifted its stake in Crispr Therapeutics by 1.0% in the second quarter. Slow Capital Inc. now owns 13,043 shares of the company's stock valued at $959,000 after purchasing an additional 130 shares during the last quarter. Flagship Harbor Advisors LLC lifted its stake in Crispr Therapeutics by 4.2% in the second quarter. Flagship Harbor Advisors LLC now owns 3,700 shares of the company's stock valued at $271,000 after purchasing an additional 150 shares during the last quarter. WASHINGTON TRUST Co lifted its stake in Crispr Therapeutics by 81.9% in the second quarter. WASHINGTON TRUST Co now owns 473 shares of the company's stock valued at $35,000 after purchasing an additional 213 shares during the last quarter. Finally, Advisor Group Holdings Inc. lifted its stake in Crispr Therapeutics by 1.2% in the second quarter. Advisor Group Holdings Inc. now owns 19,399 shares of the company's stock valued at $1,425,000 after purchasing an additional 222 shares during the last quarter. Institutional investors and hedge funds own 55.29% of the company's stock.
CRSP stock opened at $84.99 on Wednesday. The stock has a 50-day moving average price of $87.18 and a 200-day moving average price of $69.43. Crispr Therapeutics has a 1-year low of $32.30 and a 1-year high of $105.12. The firm has a market cap of $5.96 billion, a PE ratio of 184.76 and a beta of 2.29.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, July 27th. The company reported ($1.30) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.95) by ($0.35). Crispr Therapeutics had a return on equity of 2.35% and a net margin of 6.77%. The business had revenue of $0.04 million during the quarter, compared to the consensus estimate of $19.77 million. During the same period last year, the business posted ($1.01) earnings per share. The business's revenue was down 86.2% on a year-over-year basis. On average, equities analysts forecast that Crispr Therapeutics will post -4.74 earnings per share for the current year.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Read More: Stock Selection - What is cash flow?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Retail Stocks That Defied The Pandemic
When the COVID-19 pandemic struck there was no reason to think a retailer, any retailer, would be able to come out alive. After all, the economy was looking at a month or more of shut-down and most retailers survive on a thread of profits. What most analysts failed to consider is the health of the economy going into the pandemic and what that meant for spending power.
The U.S. economy was on the brink of acceleration way back in February of 2020. It was a different time, employment was at its strongest in decades and the consumer was flush. Yes, the stimulus checks helped drive the trends I am alluding to but spending on Stay-at-Home, Home-Improvement, and Outdoor Living began well before those checks were mailed.
What we are about to show you is a group of stocks that were able to defy the pandemic. Some of them were perfectly positioned for the crisis and surfed it like the wave of profits it was. Some were able to adjust and come back fighting. Others circled the wagons and waited out the storm. In all cases, the businesses are supported by a healthy eCommerce presence and benefit from brand recognition, a combination that has digital sales up triple-digits from 2019. And some of them pay a good dividend too!
View the "7 Retail Stocks That Defied The Pandemic".